无龙门架机器人SPECT术中断层成像重新定义机器人影像引导
该研究将跌落式伽马探针的数值读数与三维位置和方向注册,通过定制重建算法生成机器人SPECT(RoboSPECT)图像,在21例前列腺癌患者(10例前哨淋巴结手术、11例PSMA引导复发手术)中评估其可行性。结果显示SN-RoboSPECT识别全部26个SN-SPECT/CT病灶(100%),优于荧光成像(73%);PSMA-RoboSPECT识别全部14个PSMA-PET/CT病灶(100%),优于术前PSMA-SPECT/CT(29%),且无假阳性、切缘均干净。
要点
- RoboSPECT在SN组识别26个SN-SPECT/CT病灶达100%,荧光仅73%。
- PSMA组RoboSPECT识别14个PSMA-PET/CT病灶达100%,术前SPECT/CT仅29%。
- RoboSPECT无假阳性,所有最终切缘干净。
核心结论
- RoboSPECT提供三维空间信息,扩展跌落式伽马示踪的用途并辅助术前与术中目标感知的对齐。
- SN-RoboSPECT明显优于荧光SN成像,PSMA-RoboSPECT优于术前PSMA-SPECT/CT成像。
研究设计与样本
- 研究将伽马传感器读数与其三维位置和方向注册,用定制重建算法生成RoboSPECT图像。
- 评估21例患者:10例前哨淋巴结手术(原发性前列腺癌)和11例PSMA引导手术(复发前列腺癌)。
- RoboSPECT结果与术前PSMA-PET/CT和/或SPECT/CT及术中荧光检测(仅SN)对照。
主要发现
- SN组26个SN-SPECT/CT病灶均被SN-RoboSPECT识别(100%),其中3个肿瘤阳性(灵敏度100%)。
- SN组仅73%的前哨淋巴结在手术中荧光成像可见。
- PSMA组14个PSMA-PET/CT病灶均被PSMA-RoboSPECT显示(100%),18份标本肿瘤阳性(PSMA-PET/CT与PSMA-RoboSPECT灵敏度均为78%)。
- 术前PSMA-SPECT/CT仅识别4个PSMA病灶(29%)。
- RoboSPECT未见假阳性,所有最终切缘干净;6个月时SN组0%、PSMA组20%出现生化复发。
临床怎么用
- RoboSPECT可在术中提供三维断层成像,辅助前哨淋巴结和PSMA引导手术的目标定位与术前术中感知对齐。
- 在SN手术中,RoboSPECT对前哨淋巴结的识别优于荧光成像;在PSMA引导手术中优于术前SPECT/CT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The introduction of the drop-in gamma probe has advanced intraoperative molecular imaging during prostate cancer surgery. We have been able to convert the sensor's numeric readout to tomographic images, so-called robotic-SPECT (RoboSPECT) and investigate how this is impacted by radiopharmaceutical avidities and drop-in scan metrics. METHODS: The gamma sensor readout was registered with its 3D position and orientation, allowing a custom reconstruction algorithm to generate RoboSPECT images. Evaluations occurred in 21 patients; 10 sentinel node procedures (SN; primary prostate cancer) and 11 PSMA-radioguided surgery (recurrent prostate cancer). RoboSPECT findings were related to respective pre- and intra-operative controls, including preoperative PSMA-PET/CT and/or SPECT/CT images and fluorescence detection (SN only). RESULTS: RoboSPECT proved to be safe and applicable in a range of conditions. In the SN-group, 26 SN-SPECT/CT lesions were successfully identified with SN-RoboSPECT (100%); 3 were tumor positive (sensitivity 100%). Only 73% of SNs were surgically visible with fluorescence imaging. For the PSMA guided group, the 14 lesions identified on PSMA-PET/CT were all visualized with PSMA-RoboSPECT (100%); 18 specimens were tumor positive (sensitivity 78% for both PSMA-PET/CT and PSMA-RoboSPECT). Preoperative PSMA-SPECT/CT only identified 4 PSMA-lesions (29%). No false positives were seen for roboSPECT and all final resection margins were clean. At 6-months 0% of the SN-patients and 20% of PSMA-patients showed biochemical recurrence. CONCLUSION: RoboSPECT provides 3D context that extends the utility of drop-in gamma tracing and assists the alignment between pre- and intra-operative target perception. Here SN-RoboSPECT clearly outperformed fluorescence SN imaging and PSMA-RoboSPECT outperformed preoperative PSMA-SPECT/CT imaging.
引用
- Berrens AC, Pirkovets K, Azargoshasb S, et al. Redefining robotic image-guidance - tomographic visualization of lesions during prostate cancer surgery via gantry-free robotic SPECT. Eur J Nucl Med Mol Imaging. 2026. PMID: 42384203. doi:10.1007/s00259-026-07987-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。